Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma anchored by Keytruda ($25B cancer drug); $63.6B FY2024 revenue; Gardasil China collapse 2024 ($2B loss); Winrevair PAH approval 2024; Keytruda patent cliff 2028-2030 is defining challenge.
Merck & Co. is one of the world's largest research-driven pharmaceutical companies, founded in the United States in 1891 as a subsidiary of the German Merck KGaA and now an independent American company headquartered in Rahway, New Jersey, trading on NYSE (MRK). The company generated approximately $63.6 billion in revenues for FY2024 under CEO Robert Davis, anchored by Keytruda (pembrolizumab)—the world's best-selling cancer drug—which generated approximately $25 billion in global sales as the dominant checkpoint inhibitor immunotherapy across over 40 approved tumor indications including lung cancer, melanoma, bladder cancer, cervical cancer, and dozens more. Merck's animal health subsidiary, Merck Animal Health, is a global leader in livestock and companion animal medicines including Bravecto (flea/tick prevention) and contributes approximately $6 billion in revenues.
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.